Accelerate Diagnostics and BioCheck join the fight against COVID-19
Apr 15, 2020
On April 15, 2020, Accelerate Diagnostics and BioCheck announced a commercial supply and collaboration agreement by which Accelerate will distribute the BioCheck MS-FAST system and BioCheck SARS-CoV-2 tests in North America, Europe, and the Middle East.
The BioCheck MS-FAST system, a fully automated chemiluminescence immunoassay analyzer, and the BioCheck SARS-CoV-2 chemiluminescence-based tests are capable of processing blood, serum, or plasma samples in 30 minutes to detect IgG and IgM antibodies that confirm exposure and potential immunity to COVID-19. BioCheck has applied to receive FDA’s Emergency Use Authorization (EUA) for their SARS-Cov-2 tests.
The BioCheck SARS-COV-2 IgG/IgM test may help determine when it may be safe for recovered patients to resume normal activities
That same day, Accelerate Diagnostics announced preliminary financial results for the quarter ending March 31, 2020 and provided a business update regarding the impact of the ongoing COVID-19 pandemic on operations.
Further details on the agreement will be shared by Accelerate Diagnostics management team during the company’s first-quarter earnings call scheduled for Thursday, May 7, 2020 at 4:30PM Eastern Time. See the event for dial-in details.
Have questions about the collaboration agreement? Submit inquiries here.
- Accelerate Diagnostics Announces FDA Emergency Use Authorization for COVID-19 Individual IgM and IgG Antibody Tests
Sep 10, 2020